Image Description

INVESTORS
& MEDIA

circle

INVESTOR OVERVIEW

There are currently no events to display.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. CytokineticMore >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

03/15/17
( FY )
ALS

ALS

03/15/17
( FY )
SMA

SMA

03/15/17
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Presentation of Results From VITALITY-ALS at 28th International Symposium on ALS/MND
Previously Announced Results from Phase 3 Clinical Trial of Tirasemtiv Shared with ALS Community VITALITY-ALS Did Not Meet Primary or Secondary Endpoints Trial Informs Development of Next Generation Drug Candidate SOUTH SAN FRANCISCO, Calif. , Dec. 08, 2017 (GLOBE NEWSWIRE) -- Cytokinetics,
Toggle Summary Cytokinetics Announces Results of VITALITY-ALS to be Presented at the International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif. , Dec. 01, 2017 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq:CYTK) today announced that the results from VITALITY-ALS ( V entilatory I nvestigation of T irasemtiv and A ssessment of L ongitudinal I ndices after T reatment for a Y ear in ALS ), the
Toggle Summary New Publication Shows Respiratory Decline Correlated With Disease Progression in People Living With ALS
Retrospective Analyses of Clinical Trials in ALS Shows Faster Rate of Decline in Slow Vital Capacity Strongly Predicts Increased Risk of Future Clinical Events SOUTH SAN FRANCISCO, Calif. , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the publication of
Toggle Summary New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability and Amplification of Skeletal Muscle Response to Nerve Activation
Next Generation Fast Skeletal Muscle Activator Appears Promising Compared to Tirasemtiv in Studies of Healthy Volunteers SOUTH SAN FRANCISCO, Calif. , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the publication of results from three double-blind,

EVENTS

There are currently no events to display.